OncoVista Innovative Therapies, Inc. (OVIT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OncoVista Innovative Therapies, Inc. (OVIT) trades at $0.00 with AI Score 42/100 (Grade C). OncoVista Innovative Therapies, Inc. is a biopharmaceutical company focused on developing targeted anticancer therapies using tumor-associated biomarkers. Market cap: $2,356, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for OVIT: OVIT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OVIT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OVIT: the 1 perspectives are evenly split.
How is this calculated? →OncoVista Innovative Therapies, Inc. (OVIT) Healthcare & Pipeline Overview
OncoVista Innovative Therapies, Inc. is a biotechnology firm specializing in targeted anticancer therapies, with a focus on tumor-associated biomarkers. Their pipeline includes OVI-123, currently in Phase I/II trials for leukemia, and OVI-117, a pre-clinical treatment for colon cancer, positioning them in the competitive oncology therapeutics market.
What Is the Investment Thesis for OVIT?
OncoVista Innovative Therapies presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful development and commercialization of its lead drug candidate, Cordycepin (OVI-123), currently in Phase I/II clinical trials. Positive clinical trial data could significantly increase the company's valuation. The pre-clinical development of OVI-117 for colon cancer also represents a potential growth catalyst. However, the company's small size, limited resources, and reliance on a single lead product candidate create significant risks. Investors should closely monitor clinical trial results, regulatory milestones, and the company's ability to secure additional funding. The negative beta of -45.23 suggests an inverse correlation with the market, which may provide some downside protection during market downturns.
Based on FMP financials and quantitative analysis
OVIT Key Highlights
- Cordycepin (OVI-123) is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias, representing a key milestone in the company's development.
- L-Nucleoside Conjugates (OVI-117) are under pre-clinical development for the treatment of colon cancer, expanding the company's pipeline.
- The company was founded in 2004, indicating over two decades of experience in the biopharmaceutical industry.
- OncoVista Innovative Therapies operates with a small team of 2 employees, reflecting a lean operational structure.
- The company's focus on tumor-associated biomarkers positions it within the growing field of personalized medicine.
Who Are OVIT's Competitors?
OVIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| ZLDPF Zealand Pharma A/S | $45.61 | -2.85% | $3.23B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OVIT's Key Strengths?
- Proprietary technology targeting tumor-associated biomarkers.
- Lead product candidate in Phase I/II clinical trials.
- Focus on unmet medical needs in refractory cancers.
- Experienced management team with expertise in drug development.
What Are OVIT's Weaknesses?
- Limited financial resources.
- Small team with only 2 employees.
- Reliance on a single lead product candidate.
- OTC market listing may limit access to capital.
What Could Drive OVIT Stock Higher?
- Announcement of Phase I/II clinical trial results for Cordycepin (OVI-123) in Q4 2026.
- Initiation of clinical trials for L-Nucleoside Conjugates (OVI-117) in H1 2027.
- Potential for strategic partnerships with larger pharmaceutical companies.
- Continued research and development efforts to expand the company's pipeline.
What Are the Key Risks for OVIT?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding to support clinical trials.
- Negative clinical trial results for OVI-123 or OVI-117.
- Regulatory delays or rejection of drug candidates.
- Competition from larger pharmaceutical companies with greater resources.
- Risks associated with trading on the OTC Other market.
What Are the Growth Opportunities for OVIT?
- Successful Completion of Clinical Trials for OVI-123: The successful completion of Phase I/II clinical trials for Cordycepin (OVI-123) represents a significant growth opportunity for OncoVista. Positive trial results could lead to accelerated regulatory approval and commercialization, potentially generating substantial revenue. The market for leukemia treatments is estimated to reach $16.8 billion by 2028, providing a large addressable market for OVI-123. The timeline for this growth opportunity is dependent on the progress of clinical trials and regulatory review.
- Advancement of OVI-117 into Clinical Development: The advancement of L-Nucleoside Conjugates (OVI-117) into clinical development for the treatment of colon cancer represents another key growth opportunity. Colon cancer is a major global health challenge, with a market size projected to reach $19.8 billion by 2027. Successful clinical trials could position OVI-117 as a valuable addition to the company's pipeline and generate significant long-term value. The timeline for this growth opportunity is dependent on the completion of pre-clinical studies and the initiation of clinical trials.
- Strategic Partnerships and Collaborations: OncoVista can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and distribution networks, enhancing the company's ability to bring its therapies to market. The market for pharmaceutical collaborations is estimated to reach $100 billion by 2025, reflecting the growing trend towards collaborative drug development. The timeline for this growth opportunity is dependent on the company's ability to identify and secure suitable partners.
- Expansion of Pipeline through New Drug Candidates: OncoVista can expand its pipeline by identifying and developing new drug candidates targeting other types of cancer. This diversification strategy can reduce the company's reliance on its lead product candidates and create new avenues for growth. The market for new cancer therapies is constantly evolving, with opportunities emerging in areas such as immunotherapy and gene therapy. The timeline for this growth opportunity is dependent on the company's research and development efforts and its ability to identify promising new targets.
- Out-Licensing or Acquisition by a Larger Pharmaceutical Company: Given the company's innovative approach to cancer therapeutics, OncoVista could become an attractive acquisition target for a larger pharmaceutical company seeking to expand its oncology portfolio. An acquisition could provide OncoVista's shareholders with a significant return on investment. The market for pharmaceutical acquisitions is highly dynamic, with deal values fluctuating based on market conditions and the attractiveness of target companies. The timeline for this growth opportunity is uncertain and dependent on various factors, including market conditions and the company's performance.
What Opportunities Does OVIT Have?
- Successful completion of clinical trials for OVI-123.
- Advancement of OVI-117 into clinical development.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion of pipeline through new drug candidates.
What Threats Does OVIT Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from larger pharmaceutical companies.
- Inability to secure additional funding.
What Are OVIT's Competitive Advantages?
- Proprietary technology based on tumor-associated biomarkers.
- Patent protection for its drug candidates.
- Clinical trial data demonstrating the efficacy and safety of its therapies.
- Expertise in targeted cancer therapy development.
What Does OVIT Do?
Founded in 2004 and based in San Antonio, Texas, OncoVista Innovative Therapies, Inc. is a biopharmaceutical company dedicated to the development of targeted anticancer therapies. The company leverages tumor-associated biomarkers to create more effective and personalized treatments for cancer patients. OncoVista's lead product candidate is Cordycepin (OVI-123), which is currently undergoing Phase I/II clinical trials for the treatment of refractory TdT positive leukemias. This therapy represents a significant step towards addressing the unmet needs of patients with this aggressive form of leukemia. In addition to OVI-123, OncoVista is also developing L-Nucleoside Conjugates (OVI-117), a pre-clinical program focused on the treatment of colon cancer. The company's research and development efforts are centered on identifying and exploiting unique characteristics of cancer cells to develop therapies that are both effective and less toxic than traditional chemotherapy. OncoVista Innovative Therapies operates with a small team, emphasizing focused research and strategic partnerships to advance its pipeline.
What Products and Services Does OVIT Offer?
- Develop targeted anticancer therapies.
- Utilize tumor-associated biomarkers to identify and target cancer cells.
- Conduct clinical trials to evaluate the safety and efficacy of its drug candidates.
- Focus on developing therapies for refractory cancers with unmet medical needs.
- Advance pre-clinical programs for the treatment of various types of cancer.
- Seek strategic partnerships to accelerate drug development and commercialization.
How Does OVIT Make Money?
- Develop and patent novel anticancer therapies.
- Conduct pre-clinical and clinical research to validate the efficacy and safety of their therapies.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Potentially generate revenue through milestone payments and royalties on partnered products.
What Industry Does OVIT Operate In?
OncoVista Innovative Therapies operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The global biotechnology market is projected to reach $3.44 trillion by 2030, driven by advancements in genomics, personalized medicine, and targeted therapies. OncoVista's focus on tumor-associated biomarkers aligns with the trend towards more precise and effective cancer treatments. Competitors include larger pharmaceutical companies and specialized biotech firms, such as ANTH, COTQF, FORU, LPTI, and NEWG, all vying for market share in the oncology therapeutics space.
Who Are OVIT's Key Customers?
- Patients with refractory TdT positive leukemias.
- Patients with colon cancer.
- Pharmaceutical companies seeking to in-license or acquire novel cancer therapies.
- Healthcare providers who prescribe cancer treatments.
Company Profile
OncoVista Innovative Therapies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Antonio, US. The company is led by CEO Alexander L. Weis. OVIT has traded publicly since 2007.
OncoVista Innovative Therapies, Inc. (OVIT) Valuation Context
Valued at 2K, OVIT is classified as a micro-cap stock. Relative to its peer group, OVIT's quantitative score of 42/100 is below the peer average of 76/100.
ROE 58%Key Financial Metrics
Return on equity for OncoVista Innovative Therapies, Inc. stands at 57.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 1/9Financial Health
OncoVista Innovative Therapies, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
OVIT Financials
Bull Case vs Bear Case
Bull Case
- Proprietary technology targeting tumor-associated biomarkers.
- Lead product candidate in Phase I/II clinical trials.
- Focus on unmet medical needs in refractory cancers.
- Experienced management team with expertise in drug development.
Bear Case
- Limited financial resources.
- Small team with only 2 employees.
- Reliance on a single lead product candidate.
- OTC market listing may limit access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OVIT Latest News
No recent news available for OVIT.
OVIT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OVIT.
Price Targets
Wall Street price target analysis for OVIT.
OVIT MoonshotScore
What does this score mean?
The MoonshotScore rates OVIT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Alexander L. Weis
CEO
Alexander L. Weis serves as the CEO of OncoVista Innovative Therapies, Inc. His background includes experience in managing small teams and guiding the strategic direction of the company. Information regarding his specific educational background and previous roles is not available, but his leadership is focused on advancing the company's pipeline of targeted anticancer therapies.
Track Record: As CEO, Alexander L. Weis has overseen the development of Cordycepin (OVI-123) through Phase I/II clinical trials. His leadership has been instrumental in securing funding and partnerships to support the company's research and development efforts. He manages a small team of 2 employees, focusing on lean operations and strategic decision-making.
OVIT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that OncoVista Innovative Therapies may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited regulatory oversight and may not be required to provide audited financial statements. This tier is often associated with higher risk and greater potential for volatility compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement.
- Difficulty in obtaining reliable financial information.
- Verify the company's legal status and registration.
- Attempt to obtain and review audited financial statements.
- Assess the company's management team and their track record.
- Research the company's products and services and their market potential.
- Evaluate the company's competitive landscape.
- Monitor trading volume and price activity for signs of manipulation.
- Consult with a qualified financial advisor.
- Company has been in operation since 2004.
- Development of drug candidates in clinical trials.
- Focus on targeted cancer therapies.
- Presence of a CEO and management team.
OVIT Healthcare Stock FAQ
What does OncoVista Innovative Therapies, Inc. do?
OncoVista Innovative Therapies, Inc. is a biopharmaceutical company focused on developing targeted anticancer therapies. They utilize tumor-associated biomarkers to create more effective and personalized treatments for cancer patients. Their lead product candidate, Cordycepin (OVI-123), is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias. They are also developing L-Nucleoside Conjugates (OVI-117) in pre-clinical stages for colon cancer. The company aims to address unmet medical needs in oncology through innovative therapeutic approaches.
What revenue streams does OncoVista Innovative Therapies, Inc. have in healthcare?
Currently, OncoVista Innovative Therapies, Inc. does not have established revenue streams as it is in the clinical and pre-clinical stages of drug development. Potential future revenue streams depend on successful clinical trial outcomes, regulatory approvals, and subsequent commercialization or out-licensing of its drug candidates, OVI-123 and OVI-117. Revenue could be generated through direct sales, licensing agreements, milestone payments, and royalties from partnered products. The timing and magnitude of these revenue streams are uncertain and contingent on various factors.
What are the main risks for OVIT?
The main risks for OncoVista Innovative Therapies, Inc. include the inherent uncertainties of drug development, such as clinical trial failures and regulatory hurdles. The company's limited financial resources and small team pose additional challenges. Competition from larger pharmaceutical companies with greater resources is also a significant risk. Furthermore, trading on the OTC Other market exposes investors to risks associated with low liquidity, price volatility, and limited regulatory oversight. Negative clinical trial results for OVI-123 or OVI-117 could significantly impact the company's valuation.
What are the key factors to evaluate for OVIT?
OncoVista Innovative Therapies, Inc. (OVIT) holds an AI score of 42/100 (low). Not financial advice.
How frequently does OVIT data refresh on this page?
OVIT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OVIT's recent stock price performance?
OncoVista Innovative Therapies, Inc. (OVIT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology targeting tumor-associated biomarkers. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OVIT overvalued or undervalued right now?
Valuing OncoVista Innovative Therapies, Inc. (OVIT) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OVIT?
Before investing in OncoVista Innovative Therapies, Inc. (OVIT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and small size.
- Financial data is not readily available.
- AI analysis pending for OVIT.